Loading...
Header Logo
Keywords
Last Name
Institution

BRIAN FRANCIS CHAPIN

TitleAssistant Professor
InstitutionMD Anderson
DepartmentUrology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Baack Kukreja J, Bathala TK, Reichard CA, Troncoso P, Delacroix S, Davies B, Eggener S, Smaldone M, Minhaj Siddiqui M, Tollefson M, Chapin BF. Impact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2019 Sep 09. PMID: 31501508.
      View in: PubMed
    2. Reichard CA, Chapin BF. Editorial Comment. Urology. 2019 Sep; 131:174. PMID: 31451157.
      View in: PubMed
    3. Ranasinghe WKB, Reichard CA, Bathala T, Chapin BF. Management of cT4 Prostate Cancer. Eur Urol Focus. 2019 Jun 29. PMID: 31266732.
      View in: PubMed
    4. Ranasinghe WKB, Reichard CA, Chapin BF. Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care. Eur Urol. 2019 Nov; 76(5):543-545. PMID: 31248604.
      View in: PubMed
    5. Reichard CA, Kukreja J, Gregg JR, Bathala TK, Achim MF, Wang X, Davis JW, Nguyen QN, Chapin BF. Prediction of Organ-confined Disease in High- and Very-high-risk Prostate Cancer Patients Staged with Magnetic Resonance Imaging: Implications for Clinical Trial Design. Eur Urol Focus. 2019 May 07. PMID: 31076357.
      View in: PubMed
    6. Reichard CA, Hoffman KE, Tang C, Williams SB, Allen PK, Achim MF, Kuban DA, Chapin BF. Radical prostatectomy or radiotherapy for high- and very high-risk prostate cancer: a multidisciplinary prostate cancer clinic experience of patients eligible for either treatment. BJU Int. 2019 Apr 22. PMID: 31009137.
      View in: PubMed
    7. Chapin BF. Clinical Trials in Urology. Urol Oncol. 2019 May; 37(5):303-304. PMID: 30904395.
      View in: PubMed
    8. Sundi D, Chapin BF. Very-high-risk (VHR) localized prostate cancer: an indication for multimodal therapy. Oncotarget. 2019 Mar 08; 10(20):1870-1871. PMID: 30956769.
      View in: PubMed
    9. Reichard CA, Nyame YA, Sundi D, Tosoian J, Wilkins L, Alam R, Achim MF, Wang X, Stephenson AJ, Klein EA, Ross AE, Davis JW, Chapin BF. Does time from diagnosis to treatment of high- or very-high-risk prostate cancer affect outcome? BJU Int. 2019 Aug; 124(2):282-289. PMID: 30653804.
      View in: PubMed
    10. Gregg JR, Lopez DS, Reichard C, Zheng J, Wu W, Ye Y, Chapin B, Kim J, Daniel CR, Davis J. Coffee, Caffeine Metabolism Genotype and Disease Progression in Patients with Localized Prostate Cancer Managed with Active Surveillance. J Urol. 2019 02; 201(2):308-314. PMID: 30179617.
      View in: PubMed
    11. Gregg JR, Zheng J, Lopez DS, Reichard C, Browman G, Chapin B, Kim J, Davis J, Daniel CR. Diet quality and Gleason grade progression among localised prostate cancer patients on active surveillance. Br J Cancer. 2019 Feb; 120(4):466-471. PMID: 30679782.
      View in: PubMed
    12. Truong M, Baack Kukreja JE, Rais-Bahrami S, Barashi NS, Wang B, Nuffer Z, Park JH, Lam K, Frye TP, Nix JW, Thomas JV, Feng C, Chapin BF, Davis JW, Hollenberg G, Oto A, Eggener SE, Joseph JV, Weinberg E, Messing EM. Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance Imaging. Eur Urol Oncol. 2019 May; 2(3):257-264. PMID: 31200839.
      View in: PubMed
    13. Patel DN, Chapin BF, Freedland SJ. Response to Editorial Comment to Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital. Int J Urol. 2018 12; 25(12):1005. PMID: 30458585.
      View in: PubMed
    14. Sundi D, Tosoian JJ, Nyame YA, Alam R, Achim M, Reichard CA, Li J, Wilkins L, Schwen Z, Han M, Davis JW, Klein EA, Schaeffer EM, Stephenson AJ, Ross AE, Chapin BF. Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers. Cancer. 2019 Feb 01; 125(3):391-397. PMID: 30423193.
      View in: PubMed
    15. Patel DN, Jha S, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Chapin BF, Freedland SJ. Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital. Int J Urol. 2018 12; 25(12):998-1004. PMID: 30253446.
      View in: PubMed
    16. Jaber Y, Reichard CA, Chapin BF. Emerging role of cytoreductive prostatectomy in patients with metastatic disease. Transl Androl Urol. 2018 Sep; 7(Suppl 4):S505-S513. PMID: 30363448.
      View in: PubMed
    17. Altok M, Kim B, Patel BB, Shih YT, Ward JF, McRae SE, Chapin BF, Pisters LL, Pettaway CA, Kim J, Demirel HC, Davis JW. Cost and efficacy comparison of five prostate biopsy modalities: a platform for integrating cost into novel-platform comparative research. Prostate Cancer Prostatic Dis. 2018 11; 21(4):524-532. PMID: 29988098.
      View in: PubMed
    18. Cartapatti M, Machado RD, Muller RL, Magnabosco WJ, Santos AC, Chapin BF, Melani A, Talvane A, Tobias-Machado M, Faria EF. Synchronous abdominal tumors: is combined laparoscopic surgery in a single approach a safe option? Int Braz J Urol. 2018 May-Jun; 44(3):483-490. PMID: 29219275.
      View in: PubMed
    19. Reichard CA, Gregg JR, Achim MF, Aparicio AM, Pettaway CA, Pisters LL, Ward JF, Davis JW, Chapin BF. Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes. Eur Urol. 2018 08; 74(2):140-143. PMID: 29656854.
      View in: PubMed
    20. Altok M, Babaian K, Achim MF, Achim GC, Troncoso P, Matin SF, Chapin BF, Davis JW. Surgeon-led prostate cancer lymph node staging: pathological outcomes stratified by robot-assisted dissection templates and patient selection. BJU Int. 2018 07; 122(1):66-75. PMID: 29446205.
      View in: PubMed
    21. Reichard C, Chapin BF. Can Focal Therapy Replace Radical Therapy for Prostate Cancer? Against Focal Therapy. Eur Urol Focus. 2017 12; 3(6):524-525. PMID: 29439879.
      View in: PubMed
    22. Kukreja JB, Thompson IM, Chapin BF. Organizing a clinical trial for the new investigator. Urol Oncol. 2019 May; 37(5):336-339. PMID: 29395953.
      View in: PubMed
    23. Chapin BF, Nguyen JN, Achim MF, Navai N, Williams SB, Prokhorova IN, Wang X, Tapia EMLN, Davis JW, Troncoso P. Positive margin length and highest Gleason grade of tumor at the margin predict for biochemical recurrence after radical prostatectomy in patients with organ-confined prostate cancer. Prostate Cancer Prostatic Dis. 2018 06; 21(2):221-227. PMID: 29230008.
      View in: PubMed
    24. Li R, Ravizzini GC, Gorin MA, Maurer T, Eiber M, Cooperberg MR, Alemozzaffar M, Tollefson MK, Delacroix SE, Chapin BF. The use of PET/CT in prostate cancer. Prostate Cancer Prostatic Dis. 2018 04; 21(1):4-21. PMID: 29230009.
      View in: PubMed
    25. Chapin BF, Bellmunt J. 'Working toward understanding oligo and polymetastatic prostate cancer'. Curr Opin Urol. 2017 11; 27(6):532. PMID: 28922341.
      View in: PubMed
    26. Blanchard P, Davis JW, Frank SJ, Kim J, Pettaway CA, Pugh TJ, Pisters LL, Ward JF, Choi S, Chapin BF, Hoffman K, Navai N, Achim M, McGuire SE, Matin SF, Nguyen Q, Mahmood U, Graber WJ, Chen HC, Wang X, Kuban DA. Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU Int. 2018 04; 121(4):540-548. PMID: 28941030.
      View in: PubMed
    27. Altok M, Achim MF, Matin SF, Pettaway CA, Chapin BF, Davis JW. A decade of robot-assisted radical prostatectomy training: Time-based metrics and qualitative grading for fellows and residents. Urol Oncol. 2018 01; 36(1):13.e19-13.e25. PMID: 28964658.
      View in: PubMed
    28. Basourakos SP, Davis JW, Chapin BF, Ward JF, Pettaway CA, Pisters LL, Navai N, Achim MF, Wang X, Chen HC, Choi S, Kuban D, Troncoso P, Hanash S, Thompson TC, Kim J. Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int. 2018 01; 121(1):69-76. PMID: 28710901.
      View in: PubMed
    29. Reichard CA, Chapin BF. Local Therapy for Disseminated Prostate Cancer: Improved Outcomes or Biased Confounders? Eur Urol. 2017 09; 72(3):352-353. PMID: 28552614.
      View in: PubMed
    30. Metcalfe MJ, Chapin BF. Editorial Comment. Urology. 2017 08; 106:151-152. PMID: 28550942.
      View in: PubMed
    31. Metcalfe MJ, Smaldone MC, Lin DW, Aparicio AM, Chapin BF. Role of radical prostatectomy in metastatic prostate cancer: A review. Urol Oncol. 2017 04; 35(4):125-134. PMID: 28190749.
      View in: PubMed
    32. Williams SB, Huo J, Chamie K, Smaldone MC, Kosarek CD, Fang JE, Ynalvez LA, Kim SP, Hoffman KE, Giordano SH, Chapin BF. Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry data. Cancer. 2017 05 01; 123(9):1617-1624. PMID: 28099688.
      View in: PubMed
    33. Williams SB, Chapin BF. Patterns of Care for Prostate Cancer Patients: Predictors of Care, But For Whom? Eur Urol. 2017 05; 71(5):738-739. PMID: 27815080.
      View in: PubMed
    34. Bayne CE, Williams -B, Chapin BF. Reply to Lu Yang, Shi Qiu and Qiang Wei's Letter to the Editor re: Christopher E. Bayne, Stephen B. Williams, Matthew R. Cooperberg, et al. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. Eur Urol 2016;69:775-87. Eur Urol. 2017 02; 71(2):e51. PMID: 27461403.
      View in: PubMed
    35. Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, Mahmood U, Chen RC, Chapin BF, Kavanagh BD, Pugh TJ. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. J Clin Oncol. 2016 08 20; 34(24):2835-42. PMID: 27325855.
      View in: PubMed
    36. Ristau BT, Cahn D, Uzzo RG, Chapin BF, Smaldone MC. The role of radical prostatectomy in high-risk localized, node-positive and metastatic prostate cancer. Future Oncol. 2016 Mar; 12(5):687-99. PMID: 26839141.
      View in: PubMed
    37. Chapin BF. Optimal management of prostate cancer with lethal biology--state-of-the-art local therapy. Asian J Androl. 2015 Nov-Dec; 17(6):888-91. PMID: 26178396.
      View in: PubMed
    38. Williams SB, Davis JW, Wang X, Achim MF, Zurita-Saavedra A, Matin SF, Pisters LL, Ward JF, Pettaway CA, Chapin BF. Neoadjuvant Systemic Therapy Before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity: Contemporary Results Using the Clavien System. Clin Genitourin Cancer. 2016 Apr; 14(2):130-8. PMID: 26558524.
      View in: PubMed
    39. Davis JW, Ward JF, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE, Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim J. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 07; 118(1):68-76. PMID: 26059275.
      View in: PubMed
    40. Faria EF, Chapin BF, Muller RL, Machado RD, Reis RB, Matin SF. Radical Prostatectomy for Locally Advanced Prostate Cancer: Current Status. Urology. 2015 Jul; 86(1):10-5. PMID: 26048432.
      View in: PubMed
    41. Bayne CE, Williams SB, Cooperberg MR, Gleave ME, Graefen M, Montorsi F, Novara G, Smaldone MC, Sooriakumaran P, Wiklund PN, Chapin BF. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. Eur Urol. 2016 05; 69(5):775-87. PMID: 26003223.
      View in: PubMed
    42. Chapin BF, McGuire SE, Aparicio A. Is treatment of the primary tumor in metastatic prostate cancer justified? Eur Urol. 2014 Jun; 65(6):1067-8. PMID: 24411278.
      View in: PubMed
    43. Wirth GJ, Psutka SP, Chapin BF, Wu S, Wu CL, Dahl DM. Midterm oncological outcomes of laparoscopic vs open radical prostatectomy (RP). BJU Int. 2013 Jul; 112(2):190-7. PMID: 23601185.
      View in: PubMed
    44. Delacroix SE, Chapin BF, Wood CG. The role of lymph node dissection in renal cell carcinoma. Urol Clin North Am. 2011 Nov; 38(4):419-28, vi. PMID: 22045173.
      View in: PubMed
    45. Delacroix SE, Chapin BF, Chen JJ, Nogueras-Gonzalez GM, Tamboli P, Matin SF, Wood CG. Can a durable disease-free survival be achieved with surgical resection in patients with pathological node positive renal cell carcinoma? J Urol. 2011 Oct; 186(4):1236-41. PMID: 21849197.
      View in: PubMed
    46. Chapin BF, Delacroix SE, Wood CG. Renal cell carcinoma: what the surgeon and treating physician need to know. AJR Am J Roentgenol. 2011 Jun; 196(6):1255-62. PMID: 21606286.
      View in: PubMed
    47. Chapin BF, Delacroix SE, Culp SH, Nogueras Gonzalez GM, Tannir NM, Jonasch E, Tamboli P, Wood CG. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol. 2011 Nov; 60(5):964-71. PMID: 21621907.
      View in: PubMed
    48. Chapin BF, Delacroix SE, Wood CG. The role of lymph node dissection in renal cell carcinoma. Int J Clin Oncol. 2011 Jun; 16(3):186-94. PMID: 21523561.
      View in: PubMed
    49. Chapin BF, Wood CG. The RENAL nephrometry nomogram: statistically significant, but is it clinically relevant? Eur Urol. 2011 Aug; 60(2):249-51; discussion 251-2. PMID: 21514040.
      View in: PubMed
    50. Cost NG, Delacroix SE, Sleeper JP, Smith PJ, Youssef RF, Chapin BF, Karam JA, Culp S, Abel EJ, Brugarolas J, Raj GV, Sagalowsky AI, Wood CG, Margulis V. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol. 2011 Jun; 59(6):912-8. PMID: 21367518.
      View in: PubMed
    51. Eisner BH, Feldman AS, Chapin BF, Dretler SP. "Blind coning"--using the Stone Cone for removal of intramural ureteral calculi. Urology. 2007 Apr; 69(4):773-5. PMID: 17445670.
      View in: PubMed
    52. Oyelese Y, Tchabo JG, Chapin B, Nair A, Hanson P, McLaren R. Conservative management of uterine rupture diagnosed prenatally on the basis of sonography. J Ultrasound Med. 2003 Sep; 22(9):977-80. PMID: 14510271.
      View in: PubMed
    53. Cytoreductive nephrectomy. 109-122.
    54. Patterns of Care for Prostate Cancer Patients. European Urology.
    55. Optimal management of prostate cancer with lethal biology - State-of-the-art local therapy. Asian Journal of Andrology. 17:888-891.
    56. Treatment of the Primary Tumor in Metastatic Prostate Cancer. European Urology.
    57. The role of radical prostatectomy in high-risk localized, node-positive and metastatic prostate cancer. Future Oncology. 12:687-699.
    58. Reply to Lu Yang, Shi Qiu and Qiang Wei Letter to the Editor re. European Urology. 71:e51.
    59. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. Journal of Clinical Oncology. 34:2835-2842.
    60. Neoadjuvant Systemic Therapy before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity. Clinical Genitourinary Cancer. 14:130-138.
    CHAPIN's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description